Vaxcyte Inc

PCVX19 Jan 2025
Healthcare
$88.95
-0.03 (-2.88%)
Lowest Today
$85.28
Highest Today
$90.06
Today’s Open
$88.95
Prev. Close
$87.83
52 Week High
$121.06
52 Week Low
$58.1
To Invest in Vaxcyte Inc

Vaxcyte Inc

Healthcare
PCVX19 Jan 2025
-0.03 (-2.88%)
1M
3M
6M
1Y
5Y
Low
$85.28
Day’s Range
High
$90.06
85.28
52 Week Low
$58.1
52-Week Range
52 Week High
$121.06
58.1
1 Day
-
1 Week
+5.3%
1 month return
-0.82%
3 month return
-25.94%
6 month return
+4.58%
1 Year return
+40.96%
3 Years return
+383.75%
5 Years return
+221.71%
10 Years return
-
Institutional Holdings
FMR Inc
12.68
Vanguard Group Inc
9.18
HHG PLC
8.76
BlackRock Inc
8.56
RA Capital Management, LLC
6.97
Capital Research Global Investors
3.93
Wellington Management Company LLP
3.62

Market Status

Fundamentals
Market Cap
10631.54 mln
PB Ratio
3.2
PE Ratio
0
Enterprise Value
8478.99 mln
Total Assets
1407.92 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Organisation
Vaxcyte Inc
Employees
254
Industry
Biotechnology
CEO
Mr. Grant E. Pickering M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step